What should the optimal timing be for amifostine administration relative to radiation and chemotherapy? [5]

Journal of Clinical Oncology

Volumn 23, Issue 28, 2005, Pages 7232-7233

  Komaki, Ritsuko ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; NARCOTIC ANALGESIC AGENT; RADIOPROTECTIVE AGENT;

CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; DRUG EFFECT; ESOPHAGITIS; HUMAN; HYDRATION; HYPERALIMENTATION; LETTER; LUNG NON SMALL CELL CANCER; NONHUMAN; PATIENT ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; RADIATION DOSE; BIOASSAY; CONTROLLED CLINICAL TRIAL; DRUG ADMINISTRATION; LUNG TUMOR; METHODOLOGY; MULTIMODALITY CANCER THERAPY; NOTE; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY;

AMIFOSTINE; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; ENDPOINT DETERMINATION; HUMANS; LUNG NEOPLASMS; RADIATION-PROTECTIVE AGENTS; RANDOMIZED CONTROLLED TRIALS; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN;

EID: 27244441017     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.02.2533     Document Type: Letter

References (9)

1. Movsas B, Scott C, Langer C, et al: Randomized trial of amifostine in locally advanced non-small cell lung cancer (NSCLC) patients receiving chemotherapy and hyperfractionated radiation: Radiation Therapy Oncology Group (RTOG) 98-01. J Clin Oncol 23:2145-2154, 2005
2. Fazenbaker CA, Bachy CM, Kifle G, et al: Dose and schedule dependency of amifostine protection against hyperfractionated radiotherapy in a rat model. Proc Am Soc Clin Oncol 22:518, 2003 (abstr 2083)
3. Bachy CM, Fazenbaker CA, Kifle G, et al: Daily dosing with amifostine is necessary for full protection against oral mucositis caused by fractionated radiation in rats: Protection and pharmacokinetics. Proc Am Soc Clin Oncol 22:517, 2003 (abstr 2081)
4. Antonadou D, Coliarakis N, Synodinou M, et al: Randomized phase III trial of radiation treatment +/- amifostine in patients with advanced-stage lung cancer. Int J Radiat Oncol Biol Phys 51:915-922, 2001
5. Antonadou D, Throuvalas N, Petridis A, et al: Effect of amifostine on toxicities associated with radiochemotherapy in patients with locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 57:402-408, 2003
6. Koukourakis MI, Kyrias G, Kakolyris S, et al: Subcutaneous administration of amifostine during fractionated radiotherapy: A randomized phase II study. J Clin Oncol 18:2226-2233, 2000
7. Komaki R, Lee JS, Milas L, et al: Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: Report of a randomized comparative trial. Int J Radiat Oncol Biol Phys 58:1369-1377, 2004
8. Leong SS, Tan EH, Fong KW, et al: Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer. J Clin Oncol 21:1767-1774, 2003
9. Senzer N: A phase III randomized evaluation of amifostine in stage IIIA/IIIB non-small cell lung cancer patients receiving concurrent carboplatin, paclitaxel, and radiation therapy followed by gemcitabine and cisplatin intensification: Preliminary findings. Semin Oncol 29:38-41, 2002 (suppl 19)